Skip to main content

Milestone 9.B

Accelerate the development of the next generation CNS imaging ligands and biofluid molecular signatures targeting a variety of disease processes (neuroinflammation, bioenergetic/metabolic compromise, oxidative stress, synaptic pathology) that can be used as research tools or developed into diagnostic, prognostic, theragnostic or target engagement biomarkers.

Success Criteria

Initiate synthesis and testing of CNS imaging ligands (PET/SPECT) for at least 12 novel, prioritized candidate targets. Ensure that these reagents are made available as open source tools for target validation and predictive drug development.

Identify at least 6 multi-omic biomarker signatures (metabolomic, proteomic, cell-free RNAseq etc.) that can be quantitatively measured in peripheral fluids and have been validated across at least 3 diverse cohorts.

Time Required

2014 to 2024

Research Implementation Area


CADRO Category

B. Diagnosis, Assessment and Disease Monitoring

Activities, Funding Initiatives, and Resources

NIH PA-06-017: Development of PET and SPECT Ligands for Brain Imaging (SBIR [R4…
NIH PA-06-018: Development of PET and SPECT Ligands for Brain Imaging (SBIR [R4…
NIH PAR-15-359: Novel Approaches to Diagnosing Alzheimer's Disease & Predicting…
NIH RFA-AG-15-011: Biomarkers of Alzheimer's Disease in Down Syndrome (R01)
NIH PA-16-091: Small Business Alzheimer's Disease Research (R43/R44)
NIH PA-16-092: Small Business Alzheimer's Disease Research (R41/R42)
NIH RFA-AG-16-019: Limited Competition: Alzheimer's Disease Neuroimaging Initia…

Relevant Recommendation(s)

2012 AD Summit Recommendations: 1E